Document is current
Any future updates will be listed below
-
Authors
Rambaran, Santhuri
Maseko, Thando Glory
Lewis, Lara
Hassan-Moosa, Razia
Archary, Derseree
Ngcapu, Sinaye
Garrett, Nigel
McKinnon, Lyle R.
Padayatchi, Nesri
Naidoo, Kogieleum
Sivro, Aida
-
Funding
Funding for this research was provided by:
National Research Foundation (108038)
European and Developing Countries Clinical Trials Partnership (TMA2017SF1960, TMA2016CDF-1582)
- License Information
-
More Information
Article History
Received: 22 December 2022
Accepted: 14 July 2023
First Online: 21 July 2023
Declarations
:
: All methods were carried out in accordance with relevant guidelines and regulations. Written informed consent was obtained from all study participants prior to enrolment. CAPRISA 011 (29/01/2014, Clinicaltrials.gov, NCT02114684), was approved by Medicines Control Council of South Africa (MCC Ref: 20130510). University of KwaZulu-Natal (UKZN) Biomedical Research Ethics Committee (BREC) reviewed and approved the original studies [BFC029/13 (CAPRISA 011), E013/04 (CAPRISA 002) and BE432/12 (Healthy donors)]. The nested study presented was reviewed and approved by University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC/00000014/2019).
: Not applicable.
: The authors declare no competing interests.
